PROTHEE-PILOTE: Physiopathology of Prosthetic Joint Infections

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05551572
Collaborator
(none)
20
1

Study Details

Study Description

Brief Summary

This study aim to explore cellular responses of bone and immune cells to bacterial infections observed in patients with prosthetic joint infections. The investigators will analyze clinical data and tissue samples collected from patients undergoing surgery as part of their usual care for prosthetic joint infections. These research will be conducted on three different hospitals in Paris: Lariboisière (AP-HP), Cochin (AP-HP) and Croix Saint-Simon.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The number of prosthetic joint infections (PJI) new cases in France is estimated at 2000/2500 cases per year. PJI, mainly caused by staphylococci, are serious infections responsible for significant morbidity result of inflammation and bone destruction (osteomyelitis). Despite optimal medical and surgical management, a risk of failure and recurrence exists, which varies depending on the situation.

    In addition to the deterioration in patients' quality of life, the economic cost for the health care system is very high, in particular because of prolonged hospitalizations, complex treatments, and frequent readmissions. Thus, the adequate management of PJI is a major public health issue.

    In this context, new therapeutic approaches are urgent medical needs for the management of patients with PJI.

    Thus, the identification of the biological mechanisms (immunology, microbiology, bone physiology) underlying these infections is essential. Indeed, the impact of bacterial infections on bone homeostasis is poorly documented. Although several biological mechanisms have been suggested the host-pathogen interaction and the close links between bacterial infection and biological response of bone cells to microorganisms and their environment warrant to be explored.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Physiopathology of Prosthetic Joint Infections : a Pilot Study
    Anticipated Study Start Date :
    Oct 1, 2022
    Anticipated Primary Completion Date :
    Oct 1, 2022
    Anticipated Study Completion Date :
    Oct 1, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    septic samples

    patients undergoing revision surgery for prosthetic joint infection

    aseptic samples

    patients undergoing revision surgery for prosthetic replacement without infection

    Outcome Measures

    Primary Outcome Measures

    1. markers of bone loss [12 months]

      Immunohistochemistry detection of Tartrate-resistant acid phosphatase cells (TRAP); cathepsin K; Matrix Metalloproteinase 9 (MMP9); sclerostin

    Secondary Outcome Measures

    1. markers of cellular activity in the bone microenvironment [12 months]

      immunohistochemistry detection of nuclear factor-activated T cells c1 (NFATc1); Matrix Metalloproteinase 9 (MMP9); Fibroblast growth factor 23 (FGF23)

    2. immune-profiling of bone microenvironment [12 months]

      mapping lymphoid and myeloid cells by spectral flow cytometry assay

    3. inflammatory mediators in the bone microenvironment [12 months]

      flow cytometry quantification of cytokine producing cells

    4. differentiation between osteoclasts from mononuclear phagocytes [12 months]

      enzyme-linked immunosorbent (ELISA) and/or flow cytometry assays using specific antibodies

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • 18 years-old and older

    • Patient eligible for lower limb revision surgery (revision surgery for infected or non-infected prosthesis)

    • Patient affiliated to a social security system

    • Oral consent to the research

    Exclusion Criteria:
    • NA

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hôpital Lariboisière Paris France 75010

    Sponsors and Collaborators

    • Assistance Publique - Hôpitaux de Paris

    Investigators

    • Principal Investigator: Martine COHEN-SOLAL, MD, PhD, Assistance Publique - Hôpitaux de Paris

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Assistance Publique - Hôpitaux de Paris
    ClinicalTrials.gov Identifier:
    NCT05551572
    Other Study ID Numbers:
    • APHP220417
    First Posted:
    Sep 22, 2022
    Last Update Posted:
    Sep 22, 2022
    Last Verified:
    Sep 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Assistance Publique - Hôpitaux de Paris
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 22, 2022